Edition:
United States

Alder Biopharmaceuticals Inc (ALDR.OQ)

ALDR.OQ on NASDAQ Stock Exchange Global Market

21.90USD
23 Feb 2017
Change (% chg)

-- (--)
Prev Close
$21.90
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
184,570
52-wk High
$36.46
52-wk Low
$15.86

ALDR.OQ

Chart for ALDR.OQ

About

Alder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder's lead pivotal-stage product candidate, eptinezumab, is being evaluated... (more)

Overall

Beta: --
Market Cap(Mil.): $1,101.49
Shares Outstanding(Mil.): 50.30
Dividend: --
Yield (%): --

Financials

  ALDR.OQ Industry Sector
P/E (TTM): -- 44.59 29.71
EPS (TTM): -2.85 -- --
ROI: -31.85 -3.18 12.94
ROE: -31.85 5.86 14.09

BRIEF-Alder Biopharmaceuticals reports Q4 loss per share $0.97

* Alder Biopharmaceuticals announces fourth quarter and full year 2016 financial and operating results

Feb 23 2017

BRIEF-James Tananbaum discloses 5 pct passive stake in Alder Biopharmaceuticals

* James Tananbaum discloses 5 percent passive stake in Alder Biopharmaceuticals Inc as of October 27 - SEC filing Source text: [http://bit.ly/2emuM1p] Further company coverage:

Nov 04 2016

BRIEF-Alder BioPharmaceuticals Q3 loss per share of $0.70

* Alder BioPharmaceuticals announces third quarter 2016 financial and operating results

Oct 27 2016

BRIEF-Alder promotes Larry Benedict to executive VP of finance

* Alder Biopharmaceuticals promotes Larry Benedict to executive vice president of finance and principal accounting officer Source text for Eikon: Further company coverage:

Oct 11 2016

More From Around the Web

Earnings vs. Estimates